Harrow (HROW) Non Operating Investment Income (2017 - 2024)

Harrow's (HROW) quarterly Non Operating Investment Income came in at -$1.9 million in Q2 2024, down 169.33% year-on-year from $2.8 million in Q3 2023, and down 54.09% quarter-over-quarter from -$1.2 million in Q1 2024.

Harrow (HROW) Non Operating Investment Income (2017 - 2024) Analysis & Trends

Harrow's Non Operating Investment Income history runs 8 years deep, the most recent figure standing at -$1.9 million for Q2 2024.

  • On a quarterly basis, Non Operating Investment Income fell 169.33% year-over-year to -$1.9 million in Q2 2024; TTM through Dec 2024 was -$3.2 million, a 202.55% decrease from a year earlier, with the FY2024 full-year figure at -$3.2 million, down 202.55% from the prior year.
  • Non Operating Investment Income slipped to -$1.9 million in Q2 2024 per HROW's latest filing, from -$1.2 million in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $4.8 million in Q4 2020 and bottomed at -$10.8 million in Q1 2020.
  • The 5-year median for Non Operating Investment Income is -$893500.0 (2020), against an average of -$1.1 million.
  • Across the five-year window, Non Operating Investment Income slumped 4365.02% in 2020 and jumped 1369.06% in 2023, its largest moves.
  • Year by year, Non Operating Investment Income stood at $4.8 million in 2020, then tumbled by 131.04% to -$1.5 million in 2021, then jumped by 195.97% to $1.4 million in 2022, then sank by 70.85% to $416000.0 in 2023, then tumbled by 562.26% to -$1.9 million in 2024.
  • Per Business Quant, the three latest HROW Non Operating Investment Income figures stand at -$1.9 million (Q2 2024), -$1.2 million (Q1 2024), and $416000.0 (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Haleon 89.91 Bn 88.04 Bn - -
2 Teva Pharmaceutical Industries 35.91 Bn 32.17 Bn 1.97 Bn -
3 Zoetis 32.54 Bn 30.60 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.54 Bn 23.48 Bn 4.39 Bn -
5 United Therapeutics 23.05 Bn 20.89 Bn 648.10 Mn -
6 RedHill Biopharma 21.48 Bn 21.48 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.82 Bn 16.50 Bn 800.70 Mn -
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -
10 Harrow 1.42 Bn 1.32 Bn 27.05 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2024 -1.92 Mn
Jun 30, 2024 -1.92 Mn
Mar 31, 2024 -1.25 Mn
Mar 31, 2024 -1.25 Mn
Dec 31, 2023 416,000.00
Dec 31, 2023 416,000.00
Sep 30, 2023 1.35 Mn
Sep 30, 2023 1.35 Mn
Jun 30, 2023 -714,000.00
Jun 30, 2023 -714,000.00
Mar 31, 2023 2.04 Mn
Mar 31, 2023 2.04 Mn
Dec 31, 2022 1.43 Mn
Dec 31, 2022 1.43 Mn
Sep 30, 2022 -1.03 Mn
Sep 30, 2022 -1.03 Mn
Jun 30, 2022 -3.45 Mn
Jun 30, 2022 -3.45 Mn
Mar 31, 2022 139,000.00
Mar 31, 2022 139,000.00